ENCell Co., Ltd.

Research ENCell Co., Ltd. (456070.KQ) on Bullrun: market cap KRW 55.67B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 55.67B.

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 55.67Bn/an/an/a

Dividend history

About ENCell Co., Ltd.

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

Related stock research

South Korea stocks South Korea Healthcare stocks A-Z stock index

Other Healthcare stocks

ORIENT BIO Inc. (002630.KS) GC Corp. (005250.KS) Pharmicell Co., Ltd. (005690.KS) Kanaph Therapeutics Inc. (0082N0.KQ) Samik Pharmaceutical Company LTD. (014950.KQ) HLB Co., Ltd. (028300) Mgen Solutions Co., Ltd. (032790.KQ) Daesung Microbiological Labs. Co., Ltd. (036480.KQ) Seoulin Bioscience Co.,Ltd. (038070.KQ) Hyundai Bioscience Co., Ltd. (048410.KQ) iNtRON Biotechnology, Inc. (048530.KQ) Synergy Innovation Co., Ltd. (048870.KQ)

Frequently asked questions

What is ENCell Co., Ltd.'s market cap?

ENCell Co., Ltd.'s market capitalization is KRW 55.67B.

What does ENCell Co., Ltd. do?

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.